Table 2 Clinicopathologic Features of LGR5 positive CACs and LGR5 negative CACs
LGR5 positive CACs (N [%]) | LGR5 negative CACs (N [%]) | p | |
|---|---|---|---|
No. of Cases | 9 | 21 | |
Sex, male/female | 5 / 4 | 14 / 7 | 0.687 |
Median age (range) (y) | 53 (24–76) | 54 (31–65) | 0.557 |
Location | |||
colon | 4 (44) | 18 (86) | 0.032 |
rectum | 5 (56) | 3 (14) | |
pT stage | |||
1 | 4 (44) | 4 (19) | 0.471 |
2 | 1 (11) | 3 (14) | |
3 | 4 (44) | 11 (52) | |
4 | 0 (0) | 3 (14) | |
pN stage | |||
0 | 6 (67) | 10 (47) | 0.440 |
1 or 2 | 3 (33) | 11 (52) | |
Cancer subtypes | |||
Conventional | 8 (89) | 4 (19) | < 0.001 |
Mucinous | 0 (0) | 9 (42) | 0.029 |
Serrated | 1 (11) | 2 (10) | 1 |
LGTG | 0 (0) | 5 (24) | 0.286 |
Other | 0 (0) | 1 (5) | 1 |
Immunohistochemistry | |||
Beta- catenin nuclear expression | |||
Diffuse | 6 (67) | 2 (10) | 0.003 |
Negative/ Scattered or Focal | 3 (33) | 19 (90) | |
SATB2 | 4 (44) | 7 (33) | 0.687 |